Announcements

Cancers (ISSN: 2072-6694) is an open access journal, allowing you to have free and unlimited access to all full-text articles. We welcome you to read the following feature papers published in the first half of 2024 in the “Systematic Review or Meta-Analysis in Cancer Research” Section:

1. “Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis”
by Nina B. Curkovic, Kun Bai, Fei Ye and Douglas B. Johnson
Cancers 2024, 16(2), 340; https://doi.org/10.3390/cancers16020340
Available online: https://www.mdpi.com/2072-6694/16/2/340

2. “Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis”
by Michela Roberto, Giacomo Barchies, Blerina Resuli, Monica Verrico, Iolanda Speranza, Leonardo Cristofani, Federica Pediconi, Federica Tomao, Andrea Botticelli and Daniele Santini
Cancers 2024, 16(3), 596; https://doi.org/10.3390/cancers16030596
Available online: https://www.mdpi.com/2072-6694/16/3/596

3. “Risk Prediction Models for Oral Cancer: A Systematic Review”
by Aufia Espressivo, Z. Sienna Pan, Juliet A. Usher-Smith and Hannah Harrison
Cancers 2024, 16(3), 617; https://doi.org/10.3390/cancers16030617
Available online: https://www.mdpi.com/2072-6694/16/3/617

4. “Evaluating Radar Reflector Localisation in Targeted Axillary Dissection in Patients Undergoing Neoadjuvant Systemic Therapy for Node-Positive Early Breast Cancer: A Systematic Review and Pooled Analysis”
by Umar Wazir, Michael J. Michell, Munaser Alamoodi and Kefah Mokbel
Cancers 2024, 16(7), 1345; https://doi.org/10.3390/cancers16071345
Available online: https://www.mdpi.com/2072-6694/16/7/1345

5. “Breaking Barriers in Neuro-Oncology: A Scoping Literature Review on Invasive and Non-Invasive Techniques for Blood–Brain Barrier Disruption”
by Miłosz Pinkiewicz, Mateusz Pinkiewicz, Jerzy Walecki, Artur Zaczyński and Michał Zawadzki
Cancers 2024, 16(1), 236; https://doi.org/10.3390/cancers16010236
Available online: https://www.mdpi.com/2072-6694/16/1/236

6. “Is Unplanned Excision of Soft Tissue Sarcomas Associated with Worse Oncological Outcomes?—A Systematic Review and Meta-Analysis”
by Felipe Larios, Marcos R. Gonzalez, Kim Ruiz-Arellanos, George Aquilino E Silva and Juan Pretell-Mazzini
Cancers 2024, 16(2), 443; https://doi.org/10.3390/cancers16020443
Available online: https://www.mdpi.com/2072-6694/16/2/443

7. “Physiotherapy Interventions in Lung Cancer Patients: A Systematic Review”
by Manuel Valdivia-Martínez, Miguel Ángel Fernández-Gualda, Elena Gallegos-García, Paula Postigo-Martin, María Fernández-González and Lucía Ortiz-Comino
Cancers 2024, 16(5), 924; https://doi.org/10.3390/cancers16050924
Available online: https://www.mdpi.com/2072-6694/16/5/924

8. “Diagnostic Accuracy of Transvaginal Ultrasound and Magnetic Resonance Imaging for the Detection of Myometrial Infiltration in Endometrial Cancer: A Systematic Review and Meta-Analysis”
by István Madár, Anett Szabó, Gábor Vleskó, Péter Hegyi, Nándor Ács, Péter Fehérvári, Tamás Kói, Emma Kálovics and Gábor Szabó
Cancers 2024, 16(5), 907; https://doi.org/10.3390/cancers16050907
Available online: https://www.mdpi.com/2072-6694/16/5/907

10. “Causes and Risk Factors of Breast Cancer, What Do We Know for Sure? An Evidence Synthesis of Systematic Reviews and Meta-Analyses”
by Borghild Løyland, Ida Hellum Sandbekken, Ellen Karine Grov and Inger Utne
Cancers 2024, 16(8), 1583; https://doi.org/10.3390/cancers16081583
Available online: https://www.mdpi.com/2072-6694/16/8/1583

11. “Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors”
by Kremena Petrova Trichkova, Franziska Görtler, Line Bjørge and Cornelia Schuster
Cancers 2024, 16(2), 250; https://doi.org/10.3390/cancers16020250
Available online: https://www.mdpi.com/2072-6694/16/2/250

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Clinical Research of Cancer”, which are listed below:

1. “Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma”
by Sami Fares, Chase J. Wehrle, Hanna Hong, Keyue Sun, Chunbao Jiao, Mingyi Zhang, Abby Gross, Erlind Allkushi, Melis Uysal, Suneel Kamath et al.
Cancers 2024, 16(8), 1453; https://doi.org/10.3390/cancers16081453
Available online: https://www.mdpi.com/2072-6694/16/8/1453

2. “Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts”
by Jacqueline Schönherr, Philipp Seifert, Falk Gühne, Thomas Winkens, Falk Rauchfuß, Utz Settmacher, Martin Freesmeyer and Robert Drescher
Cancers 2024, 16(1), 235; https://doi.org/10.3390/cancers16010235
Available online: https://www.mdpi.com/2072-6694/16/1/235

3. “Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group”
by Vanessa L. Mettmann, Claudia Blattmann, Godehard Friedel, Semi Harrabi, Thekla von Kalle, Leo Kager, Matthias Kevric, Thomas Kühne, Michaela Nathrath, Benjamin Sorg et al.
Cancers 2024, 16(2), 275; https://doi.org/10.3390/cancers16020275
Available online: https://www.mdpi.com/2072-6694/16/2/275

4. “Prognostic Value of Inflammatory Burden Index in Advanced Gastric Cancer Patients Undergoing Multimodal Treatment”
by Zuzanna Pelc, Katarzyna Sędłak, Radosław Mlak, Magdalena Leśniewska, Katarzyna Mielniczek, Piotr Rola, Jacek Januszewski, Olena Zhaldak, Anna Rekowska, Katarzyna Gęca et al.
Cancers 2024, 16(4), 828; https://doi.org/10.3390/cancers16040828
Available online: https://www.mdpi.com/2072-6694/16/4/828

5. “Emerging Therapies for Glioblastoma”
by Stella Aimé Rios, Stephanie Oyervides, David Uribe, Angelica Maree Reyes, Victor Fanniel, Jonathan Vazquez and Megan Keniry
Cancers 2024, 16(8), 1485; https://doi.org/10.3390/cancers16081485
Available online: https://www.mdpi.com/2072-6694/16/8/1485

6. “Chondrosarcoma of the Femur: Is Local Recurrence Influenced by the Presence of an Extraosseous Component?”
by Minna K. Laitinen, Michael C. Parry, Guy V. Morris, Robert J. Grimer, Vaiyapuri Sumathi, Jonathan D. Stevenson and Lee M. Jeys
Cancers 2024, 16(2), 363; https://doi.org/10.3390/cancers16020363
Available online: https://www.mdpi.com/2072-6694/16/2/363

7. “Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management”
by Ying Cong, Nick Devoogdt, Philippe Lambin, Ludwig J. Dubois and Ala Yaromina
Cancers 2024, 16(2), 371; https://doi.org/10.3390/cancers16020371
Available online: https://www.mdpi.com/2072-6694/16/2/371

8. “Surgical De-Escalation for Re-Excision in Patients with a Margin Less Than 2 mm and a Diagnosis of DCIS”
by Gianluca Vanni, Marco Pellicciaro, Nicola Di Lorenzo, Rosaria Barbarino, Marco Materazzo, Federico Tacconi, Andrea Squeri, Rolando Maria D’Angelillo, Massimiliano Berrettaa and Oreste Claudio Buonomo
Cancers 2024, 16(4), 743; https://doi.org/10.3390/cancers16040743
Available online: https://www.mdpi.com/2072-6694/16/4/743

9. “The Lipidomic Signature of Glioblastoma: A Promising Frontier in Cancer Research”
by Nina Yu and Orwa Aboud
Cancers 2024, 16(6), 1089; https://doi.org/10.3390/cancers16061089
Available online: https://www.mdpi.com/2072-6694/16/6/1089

10. “Venetoclax Resistance in Acute Myeloid Leukemia”
by Sylvain Garciaz, Marie-Anne Hospital, Yves Collette and Norbert Vey
Cancers 2024, 16(6), 1091; https://doi.org/10.3390/cancers16061091
Available online: https://www.mdpi.com/2072-6694/16/6/1091

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Cancer Metastasis”, which are listed below.

1. “Synovial Sarcoma in the Extremity: Diversity of Imaging Features for Diagnosis and Prognosis”
by Eun Byul Cho, Seul Ki Lee, Jee-Young Kim and Yuri Kim
Cancers 2023, 15(19), 4860; https://doi.org/10.3390/cancers15194860
Available online: https://www.mdpi.com/2072-6694/15/19/4860

2. “DICER1 Syndrome: A Multicenter Surgical Experience and Systematic Review”
by Claudio Spinelli, Marco Ghionzoli, Linda Idrissi Sahli, Carla Guglielmo, Silvia Frascella, Silvia Romano, Carlo Ferrari, Fabrizio Gennari, Giovanni Conzo, Riccardo Morganti et al.
Cancers 2023, 15(14), 3681; https://doi.org/10.3390/cancers15143681
Available online: https://www.mdpi.com/2072-6694/15/14/3681

3. “Circulating Tumour Cells in the Prediction of Bone Metastasis”
by Siu-Wai Choi, Aria Kaiyuan Sun, Jason Pui-Yin Cheung and Jemmi Ching-Ying Ho
Cancers 2024, 16(2), 252; https://doi.org/10.3390/cancers16020252
Available online: https://www.mdpi.com/2072-6694/16/2/252

4. “Navigating Post-Operative Outcomes: A Comprehensive Reframing of an Original Graded Prognostic Assessment in Patients with Brain Metastases”
by Maria Goldberg, Michel G. Mondragon-Soto, Laura Dieringe, Ghaith Altawalbeh, Paul Pöser, Lea Baumgart, Benedikt Wiestler, Jens Gempt, Bernhard Meyer and Amir Kaywan Aftahy
Cancers 2024, 16(2), 291; https://doi.org/10.3390/cancers16020291
Available online: https://www.mdpi.com/2072-6694/16/2/291

5. “ELF5: A Molecular Clock for Breast Aging and Cancer Susceptibility”
by Masaru Miyano and Mark A. LaBarge
Cancers 2024, 16(2), 431; https://doi.org/10.3390/cancers16020431
Available online: https://www.mdpi.com/2072-6694/16/2/431

6. “Proline Metabolism in WHO G4 Gliomas Is Altered as Compared to Unaffected Brain Tissue”
by Magdalena M. Sawicka, Karol Sawicki, Marek Jadeszko, Katarzyna Bielawska, Elżbieta Supruniuk, Joanna Reszeć, Izabela Prokop-Bielenia, Barbara Polityńska, Mateusz Jadeszko, Magdalena Rybaczek et al.
Cancers 2024, 16(2), 456; https://doi.org/10.3390/cancers16020456
Available online: https://www.mdpi.com/2072-6694/16/2/456

7. “A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans”
by Jianliang Liu, Thomas P. Cundy, Dixon T. S. Woon and Nathan Lawrentschuk
Cancers 2024, 16(3), 486; https://doi.org/10.3390/cancers16030486
Available online: https://www.mdpi.com/2072-6694/16/3/486

8. “The Keratinocyte in the Picture Cutaneous Melanoma Microenvironment”
by Ramona Marrapodi and Barbara Bellei
Cancers 2024, 16(5), 913; https://doi.org/10.3390/cancers16050913
Available online: https://www.mdpi.com/2072-6694/16/5/913

9. “Immune Response and Metastasis—Links between the Metastasis Driver MACC1 and Cancer Immune Escape Strategies”
by Sebastian Torke, Wolfgang Walther and Ulrike Stein
Cancers 2024, 16(7), 1330; https://doi.org/10.3390/cancers16071330
Available online: https://www.mdpi.com/2072-6694/16/7/1330

10. “Role of the Atypical MAPK ERK3 in Cancer Growth and Progression”
by Lobna Elkhadragy, Amanda Myers and Weiwen Long
Cancers 2024, 16(7), 1381; https://doi.org/10.3390/cancers16071381
Available online: https://www.mdpi.com/2072-6694/16/7/1381

11. “Role of Hypoxia and Rac1 Inhibition in the Metastatic Cascade”
by Lobna Elkhadragy, Amanda Myers and Weiwen Long
Cancers 2024, 16(10), 1872; https://doi.org/10.3390/cancers16101872
Available online: https://www.mdpi.com/2072-6694/16/10/1872

12. “Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis”
by Niek Wijnen, Rutger C. G. Bruijnen, Evert-Jan P. A. Vonken, Hugo W. A. M. de Jong, Joep de Bruijne, Guus M. Bol, Jeroen Hagendoorn, Martijn P. W. Intven and Maarten L. J. Smits
Cancers 2024, 16(10), 1925; https://doi.org/10.3390/cancers16101925
Available online: https://www.mdpi.com/2072-6694/16/10/1925

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

We are pleased to announce that Prof. Dr. Masaharu Seno has been appointed Associate Editor of Cancers (ISSN: 2072-6694). With an extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this role.

Prof. Dr. Masaharu Seno is Head of the Laboratory of Cancer Stem Cell Engineering at the Faculty of Natural Science and Technology, Okayama University, and he is focused on finding new methods to treat this disease. “My research is focused on the development of innovative methods for cancer treatment,” says Seno. “Specifically, my group is using induced pluripotent stem cells (iPSCs) to develop cancer stem cells (CSCs). Recently, we reported that cancer stem cells produced from iPS cells and embryonic stem cells, that then differentiate, are actually necessary for the maintenance of the cancer cells themselves. Understanding the mechanism governing the initiation and development of cancer will lead a major advance for the prevention and treatment of cancer.”

Prof. Dr. Seno points out that his group’s success lies in producing cancer stem cells from normal cell-derived iPS cells, which become tumorigenic when transplanted into nude mice, retaining stem cell-like properties without introducing foreign genes and/or intended mutations. “CSCs from normal cell derived iPSCs allow to provide not only various kinds of CSCs/cancer cells under different cancer-inducing niche but also with different genetic background and for experiments,” adds Prof. Dr. Seno. “We are thinking it possible to predict individual cancer cells, which could be subjected to find optimized and customized therapy for individuals using his/her iPSC-derived CSCs. Continuing this, the accumulation of different CSCs will become a library of CSCs/cancer cells, which should help the establishment of precision medicine for cancer treatment.”

In the future, Prof. Dr. Seno plans to form a consortium with industrial partners to manage cell libraries to develop CSC libraries. Coupled with omics technology, huge amounts of data will become available from these libraries, enabling the establishment of novel systems to evaluate agents “including those which were previously withdrawn by pharmaceutical companies after clinical trials” for cancer therapy.

This research on cancer is an extension of Prof. Dr. Seno’s expertise in the design of “functional physiologically and biologically active molecules such as growth factors, cytokines, nucleases and antibodies for medicine and public health”. Other projects include the development of highly efficient, in vivo drug delivery systems (DDSs) using nano-capsules of proteins or lipids to reduce side effects associated with conventional approaches; this is a novel procedure for profiling tissues and cells for DDSs.

The following is a short Q&A with Prof. Dr. Masaharu Seno, who shared his vision for the journal with us, as well as his views of the research area and open access publishing:

1. What appealed to you about the journal?
During the 200-year or even 100-year history of cancer research, many journals have been published that focus on the disease. However, the field of cancer science appears to have become more complicated than ever due to the development of modern molecular biotechnology that opened a new era of biological science half a century ago. Meanwhile, Cancers started with vol. 1 in 2009, almost 15 years ago, and it is headquartered in Basel, which is famous for Johannes Friedrich Miescher, who discovered Nuclein. I thought that Cancers was young and flexible enough to accept new ideas and concepts, advancing the field of cancer science with intriguing discussion without being affected by old-fashioned concepts.

2. What is your vision for the journal?
Cancer is still one of the controversial fields in science. My vision is to turn the journal into an up-to-date platform for scientific discussion distinguished from other journals in the cancer/oncology field to establish a new paradigm in cancer research, incorporating novel concepts of cancer.

3. What does the future of this field of research look like?
Due to the extensive development of information technology and networking systems, as well as artificial intelligence and computers themselves, the comprehensive analysis of experimental data, which are also available in a high-throughput manner, is growing rapidly. Many scientists are currently forced to choose a scientific approach based on either pure wet biology or in silico biology such as bioinformatics, while there are many obstacles to mastering the entire field. Scientists will have to be more thoughtful than ever, asking themselves whether they can understand the results of their analyses logically and objectively. It will become more important to be open-minded so that future scientists can gain the interdisciplinary knowledge required to collaborate with people in different fields. We can find such cases of collaboration in history such as the discovery of the DNA double-helix model by James D. Watson, Francis Crick and Rosalind Franklin (1953) and the proposal of the neuronal network model by Wallen S. McCulloch and Walter Pitts (1943).

4. What do you think of the development of open access in the publishing field?
The problem of open access for the authors is usually the cost of publication, which is not always easy to pay for from their research budget. However, it is true that the papers published under open access are easy to read, resulting in the widespread propagation of their contents. I think it is being accepted as a good contemporary manner of publication because the system appears compromised by publishers and academic organizations making contracts with each of the supporting authors.

We warmly welcome our new Associate Editor, Prof. Dr. Masaharu Seno, and wish the journal every success in the future.

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Tumor Microenvironment”, which are listed below:

1. “Contribution of Autophagy to Epithelial Mesenchymal Transition Induction during Cancer Progression”
by Raffaele Strippoli, Reyhaneh Niayesh-Mehr, Maryam Adelipour, Arezoo Khosravi, Ali Zarrabi and Abdolamir Allameh
Cancers 2024, 16(4), 807; https://doi.org/10.3390/cancers16040807
Available online: https://www.mdpi.com/2072-6694/16/4/807

2. “CSF-1R in Cancer: More than a Myeloid Cell Receptor”
by Francesca Cersosimo, Silvia Lonardi, Cristina Ulivieri, Paolo Martini, William Vermi, Antonio Giordano and Emanuele Giurisato
Cancers 2024, 16(2), 282; https://doi.org/10.3390/cancers16020282
Available online: https://www.mdpi.com/2072-6694/16/2/282

3. “Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma—Recent Advances”
by Adrian Kowalczyk, Julia Zarychta, Anna Marszołek, Joanna Zawitkowska and Monika Lejman
Cancers 2024, 16(3), 623; https://doi.org/10.3390/cancers16030623
Available online: https://www.mdpi.com/2072-6694/16/3/623

4. “Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development”
by Nimrod S. Barashi, Tiandao Li, Duminduni H. Angappulige, Bo Zhang, Harry O’Gorman, Charles U. Nottingham, Anup S. Shetty, Joseph E. Ippolito, Nupam P.Mahajan, Eric H. Kim et al.
Cancers 2024, 16(1), 213; https://doi.org/10.3390/cancers16010213
Available online: https://www.mdpi.com/2072-6694/16/1/213

5. “CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture”
by Maraike Harfmann, Tanja Schröder, Dawid Głów, Maximilian Jung, Almut Uhde, Nicolaus Kröger, Stefan Horn, Kristoffer Riecken, Boris Fehse and Francis A. Ayuk
Cancers 2024, 16(2), 334; https://doi.org/10.3390/cancers16020334
Available online: https://www.mdpi.com/2072-6694/16/2/334

6. “The Aryl Hydrocarbon Receptor: Impact on the Tumor Immune Microenvironment and Modulation as a Potential Therapy”
by Brian D. Griffith and Timothy L. Franke
Cancers 2024, 16(3), 472; https://doi.org/10.3390/cancers16030472
Available online: https://www.mdpi.com/2072-6694/16/3/472

7. “Therapeutic Immunomodulation in Gastric Cancer”
by Venu Akkanapally, Xue-Feng Bai and Sujit Basu
Cancers 2024, 16(3), 560; https://doi.org/10.3390/cancers16030560
Available online: https://www.mdpi.com/2072-6694/16/3/560

8. “Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer”
by Keila S. Espinoza and Ashley J. Snider
Cancers 2024, 16(4), 789; https://doi.org/10.3390/cancers16040789
Available online: https://www.mdpi.com/2072-6694/16/4/789

9. “The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway”
by Vasiliki Zoi, Athanassios P. Kyritsis, Vasiliki Galani, Diamanto Lazari, Spyridon Voulgaris and Georgios A. Alexiou
Cancers 2024, 16(8), 1554; https://doi.org/10.3390/cancers16081554
Available online: https://www.mdpi.com/2072-6694/16/8/1554

10. “Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence”
by Mariia Ivanova, Carlo Pescia, Eltjona Mane, Dario Trapani, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elham Sajjadi, Francesca Maria Porta, Cristian Scatena et al.
Cancers 2024, 16(11), 1981; https://doi.org/10.3390/cancers16111981
Available online: https://www.mdpi.com/2072-6694/16/11/1981

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Infectious Agents and Cancer”, which are listed below:

1. “Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies”
by Luvita Suryani, Hazel P. Y. Lee, Wei Keat Teo, Zhi Kang Chin, Kwok Seng Loh and Joshua K. Tay
Cancers 2024, 16(5), 918; https://doi.org/10.3390/cancers16050918
Available online: https://www.mdpi.com/2072-6694/16/5/918

2. “Cultivable Microbiome Approach Applied to Cervical Cancer Exploration”
by Irma Berenice Mulato-Briones, Ismael Olan Rodriguez-Ildefonso, Julián Antonio Jiménez-Tenorio, Patricia Isidra Cauich-Sánchez, María del Socorro Méndez-Tovar, Gerardo Aparicio-Ozores, María Yicel Bautista-Hernández, Juan Francisco González-Parra, Jesús Cruz-Hernández, Ricardo López-Romero et al.
Cancers 2024, 16(2), 314; https://doi.org/10.3390/cancers16020314
Available online: https://www.mdpi.com/2072-6694/16/2/314

3. “COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant”
by Joaquín Martínez-López, Javier de la Cruz, Rodrigo Gil-Manso, José María Aspa-Cilleruelo, Víctor Jiménez Yuste, Cristian Escolano Escobar, Javier López-Jiménez, Cristina Jacome Yerovi, José-Ángel Hernández-Rivas, Rafael Duarte et al.
Cancers 2024, 16(2), 379; https://doi.org/10.3390/cancers16020379
Available online: https://www.mdpi.com/2072-6694/16/2/379

4. “Cancer and HIV: The Molecular Mechanisms of the Deadly Duo”
by Aadilah Omar,Natasia Marques and Nicole Crawford
Cancers 2024, 16(3), 546; https://doi.org/10.3390/cancers16030546
Available online: https://www.mdpi.com/2072-6694/16/3/546

5. “Epigenetic Mechanisms in Latent Epstein-Barr Virus Infection and Associated Cancers”
by Atharva S. Torne and Erle S. Robertson
Cancers 2024, 16(5), 991; https://doi.org/10.3390/cancers16050991
Available online: https://www.mdpi.com/2072-6694/16/5/991

6. “Hepatitis-C-Related Hepatocellular Carcinoma, Still a Relevant Etiology beyond a Hepatitis C Infection Cure”
by Elena Vargas-Accarino, Mónica Higuera, María Buti and Beatriz Mínguez
Cancers 2024, 16(8), 1521; https://doi.org/10.3390/cancers16081521
Available online: https://www.mdpi.com/2072-6694/16/8/1521

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Methods and Technologies Development”, which are listed below:

1. “Incidence and Risk Assessment of Capsular Contracture in Breast Cancer Patients following Post-Mastectomy Radiotherapy and Implant-Based Reconstruction”
by Maria Vinsensia, Riccarda Schaub, Eva Meixner, Philipp Hoegen, Nathalie Arians, Tobias Forster, Line Hoeltgen, Clara Köhler, Kristin Uzun-Lang, Vania Batista et al.
Cancers 2024, 16(2), 265; https://doi.org/10.3390/cancers16020265
Available online: https://www.mdpi.com/2072-6694/16/2/265

2. “Expanding Our Knowledge of DICER1 Gene Alterations and Their Role in Thyroid Diseases”
by Maria Cristina Riascos, Anh Huynh, William C. Faquin and Vania Nosé
Cancers 2024, 16(2), 347; https://doi.org/10.3390/cancers16020347
Available online: https://www.mdpi.com/2072-6694/16/2/347

3. “Assessment of Narrow-Band Imaging Algorithm for Video Capsule Endoscopy Based on Decorrelated Color Space for Esophageal Cancer: Part II, Detection and Classification of Esophageal Cancer”
by Yu-Jen Fang, Chien-Wei Huang, Riya Karmakar, Arvind Mukundan, Yu-Ming Tsao, Kai-Yao Yang and Hsiang-Chen Wang
Cancers 2024, 16(3), 572; https://doi.org/10.3390/cancers16030572
Available online: https://www.mdpi.com/2072-6694/16/3/572

4. “Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors”
by Paniz Sabeghi, Paniz Zarand, Sina Zargham, Batis Golestany, Arya Shariat, Myles Chang, Evan Yang, Priya Rajagopalan, Daniel Chang Phung and Ali Gholamrezanezhad
Cancers 2024, 16(3), 576; https://doi.org/10.3390/cancers16030576
Available online: https://www.mdpi.com/2072-6694/16/3/576

5. “Identification of Skin Lesions by Snapshot Hyperspectral Imaging”
by Hung-Yi Huang, Hong-Thai Nguyen, Teng-Li Lin, Penchun Saenprasarn, Ping-Hung Liu and Hsiang-Chen Wang
Cancers 2024, 16(1), 217; https://doi.org/10.3390/cancers16010217
Available online: https://www.mdpi.com/2072-6694/16/1/217

7. “A Comprehensive Investigation of Active Learning Strategies for Conducting Anti-Cancer Drug Screening”
by Priyanka Vasanthakumari, Yitan Zhu, Thomas Brettin, Alexander Partin, Maulik Shukla, Fangfang Xia, Oleksandr Narykov, Michael Ryan Weil and Rick L. Stevens
Cancers 2024, 16(3), 530; https://doi.org/10.3390/cancers16030530
Available online: https://www.mdpi.com/2072-6694/16/3/530

8. “New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine”
by Fernardo Alberca-del Arco, Daniel Prieto-Cuadra, Rocio Santos-Perez de la Blanca, Felipe Sáez-Barranquero, Elisa Matas-Rico and Bernardo Herrera-Imbroda
Cancers 2024, 16(4), 803; https://doi.org/10.3390/cancers16040803
Available online: https://www.mdpi.com/2072-6694/16/4/803

9. “The Rise of Hypothesis-Driven Artificial Intelligence in Oncology”
by Zilin Xianyu, Cristina Correia, Choong Yong Ung, Shizhen Zhu, Daniel D. Billadeau and Hu Li
Cancers 2024, 16(4), 822; https://doi.org/10.3390/cancers16040822
Available online: https://www.mdpi.com/2072-6694/16/4/822

10. “Integrating Artificial Intelligence for Advancing Multiple-Cancer Early Detection via Serum Biomarkers: A Narrative Review”
by Hsin-Yao Wang, Wan-Ying Lin, Chenfei Zhou, Zih-Ang Yang, Sriram Kalpana and Michael S. Lebowitz
Cancers 2024, 16(5), 862; https://doi.org/10.3390/cancers16050862
Available online: https://www.mdpi.com/2072-6694/16/5/862

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Molecular Cancer Biology”, which are listed below:

1. “MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges”
by Anju G. S. Phoolchund and Salim I. Khakoo
Cancers 2024, 16(2), 259; https://doi.org/10.3390/cancers16020259
Available online: https://www.mdpi.com/2072-6694/16/2/259

2. “The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer”
by Qingming Fang
Cancers 2024, 16(2), 331; https://doi.org/10.3390/cancers16020331
Available online: https://www.mdpi.com/2072-6694/16/2/331

3. “Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer”
by Qiao-Hong Chen, Erick Munoz and Dennis Ashong
Cancers 2024, 16(3), 663; https://doi.org/10.3390/cancers16030663
Available online: https://www.mdpi.com/2072-6694/16/3/663

4. “Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells”
by Youssef Al Hmada, Robert T. Brodell, Naji Kharouf, Thomas W. Flanagan, Abdulhadi A. Alamodi, Sofie-Yasmin Hassan, Hosam Shalaby, Sarah-Lilly Hassan, Youssef Haikel, Mosaad Megahed et al.
Cancers 2024, 16(2), 470; https://doi.org/10.3390/cancers16020470
Available online: https://www.mdpi.com/2072-6694/16/2/470

5. “Glioma–Immune Cell Crosstalk in Tumor Progression”
by Mahmoud Elguindy, Jacob S. Young, Isha Mondal, Rongze O. Lu and Winson S. Ho
Cancers 2024, 16(2), 308; https://doi.org/10.3390/cancers16020308
Available online: https://www.mdpi.com/2072-6694/16/2/308

6. “Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review”
by Shigekatsu Maekawa, Ryo Takata and Wataru Obara
Cancers 2024, 16(3), 523; https://doi.org/10.3390/cancers16030523
Available online: https://www.mdpi.com/2072-6694/16/3/523

7. “Characteristics of Cancer Stem Cells and Their Potential Role in Endometrial Cancer”
by Karolina Frąszczak and Bartłomiej Barczyński
Cancers 2024, 16(6), 1083; https://doi.org/10.3390/cancers16061083
Available online: https://www.mdpi.com/2072-6694/16/6/1083

8. “Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer”
by Maciej Jaromin, Tomasz Konecki and Piotr Kutwin
Cancers 2024, 16(7), 1366; https://doi.org/10.3390/cancers16071366
Available online: https://www.mdpi.com/2072-6694/16/7/1366

9. “Transforming Growth Factor-β/Smad Signaling Inhibits Melanoma Cancer Stem Cell Self-Renewal, Tumor Formation and Metastasis”
by Julien Boudreault, Ni Wang, Mostafa Ghozlan and Jean-Jacques Lebrun
Cancers 2024, 16(1), 224; https://doi.org/10.3390/cancers16010224
Available online: https://www.mdpi.com/2072-6694/16/1/224

10. “The Tumor Suppressor SOCS1 Diminishes Tolerance to Oxidative Stress in Hepatocellular Carcinoma”
by Akhil Shukla, Md Gulam Musawwir Khan, Anny Armas Cayarga, Mozhdeh Namvarpour, Mohammad Mobarak H. Chowdhury, Dominique Levesque, Jean-François Lucier, François-Michel Boisvert, Sheela Ramanathan and Subburaj Ilangumaran
Cancers 2024, 16(2), 292; https://doi.org/10.3390/cancers16020292
Available online: https://www.mdpi.com/2072-6694/16/2/292

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

MDPI’s Best PhD Thesis Awards are granted to promising young scholars whose PhD theses are deemed exceptional within their respective research fields. These awards aim to encourage young scholars to continue their outstanding accomplishments and further contribute to their field.

We extend our heartfelt congratulations to the 54 winners of the 2023 Best PhD Thesis Awards and wish them success with their future research endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

The 2024 International Conference of the Korean Society for Molecular and Cellular Biology will be held from 8 to 11 October 2024, in Jeju, Republic of Korea. The conference is organized by the Korean Society for Molecular and Cellular Biology, and promises a rich tapestry of scholarly exchange across various disciplines within biological and biomedical sciences.

The conference will feature four top keynote speakers in the field of life sciences, including two Nobel Prize winners, and scientists from more than thirty countries around the world participating in more than twenty scientific sessions on a variety of topics. The agenda includes symposiums showcasing pioneering research in life sciences, dedicated sessions for young academics, such as graduate students, postdoctoral researchers, and research professors, and a Bio Job Fair.

The following MDPI journals will be represented at the conference:

• International Journal of Molecular Sciences;
• Antioxidants;
• Biophysica;
• Current Issues in Molecular Biology;
• Kinases and Phosphatases;
• Metabolites;
• Microorganisms;
• Proteomes;
• Bioengineering;
• Biomedicines;
• BioMed;
• Biomolecules;
• Cancers;
• Genes;
• Journal of Molecular Pathology;
• Organoids;
• Plants;
• Non-Coding RNA;
• Sci;
• Journal of Fungi.

If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #99 and answering any questions that you may have. For more information about the conference, please visit the following link: https://www.ksmcb.or.kr/icksmcb2024/main.html.